Wall Street Rallies as Domestic and Global Economic Data Favors Buying

Michael Teague |

Investors on Wall Street took heart in economic data on Tuesday, putting a stop to two straight sessions of heavy selling by the closing bell as stocks rallied across the board.

The street kept in mind the relatively brutal US winter season, and was unflinching at the Department of Commerce’s new home sales report for the month of February that indicated contracts to buy new homes during the period were off by 3.3 percent. Meanwhile, there were bright spots in the form of the Conference Board’s index of consumer conference that showed a reading of 82.3 for the month of March, a significant jump from the previous month’s 78.3, and well ahead of forecasts for a reading of 78.5.

On the international scene, succor came from financial giant Morgan Stanley (MS) , who reiterated its buy recommendation on Chinese stocks, and was flatly dismissive of the growing consensus that the world’s most populous nation and economic lynch-pin would enter a downturn significant enough to disrupt global markets.


Results for Tuesday, March 25

●       Standard & Poor’s 500: +0.44 percent to 1,865.62

●       Dow Jones Industrial Average: +0.56 percent to 16,367.88

●       NASDAQ: +0.19 percent to 4,234.27


Our Top Stories

●       George Brooks offers the argument that though the bull market may run in to some corrections, it is still a ways off from topping out.

●       Andy Waldock has some tips for how to play the copper market in the face of weaker pricing.

●       Senior Editor Jacob Harper chimes in with a pair of tech pieces, one on the upcoming IPO for King Digital Entertainment maker of the incomprehensibly popular Candy Crush Saga app, and another on how Facebook’s (FB) new platform changes reflect a company that is shifting priorities towards the needs of shareholders, rather than CEO Mark Zuckerberg’s vision of a more open and connected world.

●       The Life Sciences Report talks micro-cap biotech stocks with Roadmap Capital CEO and Founder Hugh Cleland.


On the Exchanges

●       After announcing a deal to issue 2 million shares of common stock, plucky little biofuel outfit MagneGas Corporation (MNGA) wiped out much of the astronomical gains made over the past few sessions, with shares down nearly 30 percent by the close.

●       Russian ETFs rallied higher again, despite the announcement that the former Soviet Union had been given a time-out from the group of eight industrial nations.

●       Equities.com Small-Cap Star Shenandoah Telecommunications (SHEN) dropped over one percent by the closing bell, though Senior Editor Joel Andersonsees a lot to like in the stock’s 2014 performance so far.

●       Small-cap medical test-maker BG Medicine (BGMD) hit a new 52-week high after the American Heart Journal published results that were achieved using one of its Galectin-3 tests.

●       Six high-yielding blue-chip banks for your consideration.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
FB Facebook Inc. 129.69 -1.35 -1.03 16,719,600
MNGA MagneGas Corporation 0.71 -0.00 -0.49 614,713
MS Morgan Stanley 33.82 0.43 1.29 12,606,564
PBEIF PT Bentoel International Investama TBK n/a n/a n/a 0
SHEN Shenandoah Telecommunications Co 26.10 0.10 0.38 106,693


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.